{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:07:42Z","timestamp":1792688862715,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Little effort has been made to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance (MGUS) of the immunoglobulin M (IgM) class, which progresses to lymphoma or Waldenstro\u0308m macroglobulinemia, whereas IgA and IgG MGUS progress to multiple myeloma, primary amyloidosis (AL), or a related plasma cell disorder. From 1960 to 1994, IgM MGUS was diagnosed in 213 patients in southeastern Minnesota. The end point was progression to lymphoma or a related disorder, as assessed with the Kaplan-Meier method. The 213 patients were followed up for 1567 person-years (median, 6.3 years per patient). Lymphoma developed in 17 patients (relative risk [RR], 14.8), Waldenstro\u0308m macroglobulinemia in 6 (RR, 262), primary amyloidosis in 3 (RR, 16.3), and chronic lymphocytic leukemia in 3 (RR, 5.7). The relative risk of progression was 16-fold higher in the patients with IgM MGUS than in the white population of the Iowa Surveillance, Epidemiology, and End Results Program. Cumulative incidence of progression was 10% at 5 years, 18% at 10 years, and 24% at 15 years. On multivariate analysis, the serum monoclonal protein and serum albumin concentrations at diagnosis were the only risk factors for progression to lymphoma or a related disorder. Risk for progression to lymphoma or a related disorder at 10 years after the diagnosis of MGUS was 14% with an initial monoclonal protein concentration of 0.5 g\/dL or less, 26% with 1.5 g\/dL, 34% for 2.0 g\/dL, and 41% for more than 2.5 g\/dL. (Blood. 2003;102:3759-3764)<\/jats:p>","DOI":"10.1182\/blood-2003-03-0801","type":"journal-article","created":{"date-parts":[[2003,7,29]],"date-time":"2003-07-29T00:26:58Z","timestamp":1059438418000},"page":"3759-3764","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":271,"title":["Long-term follow-up of IgM monoclonal gammopathy of undetermined significance"],"prefix":"10.1182","volume":"102","author":[{"given":"Robert A.","family":"Kyle","sequence":"first","affiliation":[{"name":"From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry M.","family":"Therneau","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen D.","family":"Remstein","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice R.","family":"Offord","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk R.","family":"Larson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Plevak","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"L. Joseph","family":"Melton","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021221512234500_REF1","doi-asserted-by":"crossref","unstructured":"Ha\u0308lle\u0301n J. Frequency of \u201cabnormal\u201d serum globulins (M-components) in the aged. Acta Med Scand.1963;173: 737-744.","DOI":"10.1111\/j.0954-6820.1963.tb17460.x"},{"key":"2020021221512234500_","unstructured":"Ha\u0308lle\u0301n J. Discrete gammaglobulin (M-)components in serum: clinical study of 150 subjects without myelomatosis. Acta Med Scand Suppl.1966;462: 1-127."},{"key":"2020021221512234500_","doi-asserted-by":"crossref","unstructured":"Axelsson U, Bachmann R, Ha\u0308lle\u0301n J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand.1966;179: 235-247.","DOI":"10.1111\/j.0954-6820.1966.tb05453.x"},{"key":"2020021221512234500_","doi-asserted-by":"crossref","unstructured":"Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood.1972;40: 719-724.","DOI":"10.1182\/blood.V40.5.719.719"},{"key":"2020021221512234500_REF5","doi-asserted-by":"crossref","unstructured":"Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol.1982;35: 63-68.","DOI":"10.1136\/jcp.35.1.63"},{"key":"2020021221512234500_REF6","doi-asserted-by":"crossref","unstructured":"Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med.1978;64: 814-826.","DOI":"10.1016\/0002-9343(78)90522-3"},{"key":"2020021221512234500_REF7","doi-asserted-by":"crossref","unstructured":"Kyle RA. \u201cBenign\u201d monoclonal gammopathy: after 20 to 35 years of follow-up. Mayo Clin Proc.1993;68: 26-36.","DOI":"10.1016\/S0025-6196(12)60015-9"},{"key":"2020021221512234500_REF8","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med.2002;346: 564-569.","DOI":"10.1056\/NEJMoa01133202"},{"key":"2020021221512234500_REF9","doi-asserted-by":"crossref","unstructured":"Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc.1987;62: 719-731.","DOI":"10.1016\/S0025-6196(12)65225-2"},{"key":"2020021221512234500_REF10","doi-asserted-by":"crossref","unstructured":"Hobbs JR, Carter PM, Cooke KB, Foster M, Oon C-J. IgM paraproteins. J Clin Pathol.1974;28(suppl 6): 54-64.","DOI":"10.1136\/jcp.s1-6.1.54"},{"key":"2020021221512234500_REF11","doi-asserted-by":"crossref","unstructured":"Stein RS, Ellman L, Bloch KJ. The clinical correlates of IgM M-components: an analysis of thirty-four patients. Am J Med Sci.1975;269: 209-216.","DOI":"10.1097\/00000441-197503000-00007"},{"key":"2020021221512234500_REF12","doi-asserted-by":"crossref","unstructured":"Tubbs RR, Hoffman GC, Deodhar SD, Hewlett JS. IgM monoclonal gammopathy: histopathologic and clinical spectrum. Cleve Clin Q.1976;43: 217-235.","DOI":"10.3949\/ccjm.43.4.217"},{"key":"2020021221512234500_REF13","doi-asserted-by":"crossref","unstructured":"Waldenstro\u0308m JG. Benign monoclonal gammopathy. Acta Med Scand.1984;216: 435-447.","DOI":"10.1111\/j.0954-6820.1984.tb05032.x"},{"key":"2020021221512234500_REF14","doi-asserted-by":"crossref","unstructured":"Gregersen H, Ibsen J, Mellemkjoer L, Dahlerup J, Olsen J, Sorensen H. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol.2001;112: 353-357.","DOI":"10.1046\/j.1365-2141.2001.02533.x"},{"key":"2020021221512234500_REF15","doi-asserted-by":"crossref","unstructured":"Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol.2002;20: 1625-1634.","DOI":"10.1200\/JCO.20.6.1625"},{"key":"2020021221512234500_REF16","unstructured":"Kyle RA, Katzmann JA, Lust JA, Dispenzieri A. Immunochemical characterization of immunoglobulins. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical Laboratory Immunology. 6th ed. Washington, DC: ASM Press; 2002: 71-91."},{"key":"2020021221512234500_REF17","doi-asserted-by":"crossref","unstructured":"Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc.1996;71: 266-274.","DOI":"10.4065\/71.3.266"},{"key":"2020021221512234500_REF18","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc.1958;53: 457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2020021221512234500_REF19","doi-asserted-by":"crossref","unstructured":"Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [A].1972;135: 185-207.","DOI":"10.2307\/2344317"},{"key":"2020021221512234500_REF20","doi-asserted-by":"crossref","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med.1999;18: 695-706.","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"2020021221512234500_REF21","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc [B].1972;34: 187-220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2020021221512234500_REF22","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data CD Rom (1973-1997). Bethesda, MD: National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch. Released April 2000; based on the August 1999 submission."},{"key":"2020021221512234500_REF23","doi-asserted-by":"crossref","unstructured":"Berry G. The analysis of mortality by the subject-years method. Biometrics.1983;39: 173-184.","DOI":"10.2307\/2530817"},{"key":"2020021221512234500_REF24","doi-asserted-by":"crossref","unstructured":"Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood.2002;100: 1417-1424.","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424"},{"key":"2020021221512234500_REF25","doi-asserted-by":"crossref","unstructured":"Pasqualetti P, Festuccia V, Collacciani A, Casale R. The natural history of monoclonal gammopathy of undetermined significance: a 5- to 20-year follow-up of 263 cases. Acta Haematol.1997;97: 174-179.","DOI":"10.1159\/000203676"},{"key":"2020021221512234500_REF26","doi-asserted-by":"crossref","unstructured":"Owen RG, Parapia LA, Higginson J, et al. Clinicopathological correlates of IgM paraproteinemias. Clin Lymphoma.2000;1: 39-43.","DOI":"10.3816\/CLM.2000.n.003"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/10\/3759\/1691150\/h82203003759.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/10\/3759\/1691150\/h82203003759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T20:45:29Z","timestamp":1585082729000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/10\/3759\/16960\/Longterm-followup-of-IgM-monoclonal-gammopathy-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,15]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-03-0801","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,15]]}}}